Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Crescent Biopharma (CBIO) EPS (Basic) (2016 - 2026)

Crescent Biopharma (CBIO) has disclosed EPS (Basic) for 12 consecutive years, with -$0.84 as the latest value for Q1 2026.

  • For Q1 2026, EPS (Basic) fell 2011.11% year-over-year to -$0.84; the TTM value through Mar 2026 reached -$7.46, down 1335.49%, while the annual FY2025 figure was -$5.59, 846.84% down from the prior year.
  • EPS (Basic) hit -$0.84 in Q1 2026 for Crescent Biopharma, up from -$3.28 in the prior quarter.
  • Across five years, EPS (Basic) topped out at -$0.04 in Q1 2025 and bottomed at -$3.28 in Q4 2025.
  • Average EPS (Basic) over 5 years is -$0.59, with a median of -$0.17 recorded in 2023.
  • Year-over-year, EPS (Basic) skyrocketed 76.47% in 2025 and then plummeted 2011.11% in 2026.
  • Crescent Biopharma's EPS (Basic) stood at -$0.19 in 2022, then rose by 26.32% to -$0.14 in 2023, then fell by 7.14% to -$0.15 in 2024, then tumbled by 2086.93% to -$3.28 in 2025, then surged by 74.26% to -$0.84 in 2026.
  • According to Business Quant data, EPS (Basic) over the past three periods came in at -$0.84, -$3.28, and -$1.77 for Q1 2026, Q4 2025, and Q3 2025 respectively.